Bisretinoid lipofuscin (A2E)

Bisretinoid lipofuscin refers to a group of fluorescent, non-degradable pigments that accumulate within the lysosomes of retinal pigment epithelial (RPE) cells as a byproduct of the visual cycle. The most well-characterized component is N-retinylidene-N-retinylethanolamine (A2E), which forms through the non-enzymatic reaction of all-trans-retinal with phosphatidylethanolamine in photoreceptor outer segments (Sparrow et al., 2012, Prog Retin Eye Res). While small amounts accumulate naturally with age, excessive accumulation is highly phototoxic and leads to RPE cell death and subsequent photoreceptor loss. This process is the primary driver of Stargardt disease, caused by mutations in the ABCA4 transporter, and is a major contributing factor to the progression of geographic atrophy in dry age-related macular degeneration (Radu et al., 2011, PNAS). Therapeutic targeting of bisretinoid lipofuscin focuses on preventing its formation or accelerating its removal to preserve vision. Current clinical strategies include the use of RPE65 inhibitors like Emixustat to slow the visual cycle, and RBP4 antagonists like Tinlarebant to reduce the delivery of vitamin A to the retina (Boyer et al., 2012, JAMA Ophthalmol). Another novel approach, ALK-001, utilizes chemically modified (deuterated) vitamin A that is more resistant to the dimerization process that creates A2E. Because these pigments are naturally fluorescent, fundus autofluorescence (FAF) serves as a critical non-invasive biomarker for monitoring target accumulation and the efficacy of these interventions in clinical trials (Charbel Issa et al., 2013, Prog Retin Eye Res).

Other names

N-retinylidene-N-retinylethanolamineRetinal lipofuscinOcular lipofuscinA2E and related bisretinoidsRetinoid-derived pigments

Reduction of bisretinoid formation by inhibiting visual cycle enzymes (e.g., RPE65), reducing serum retinol levels via RBP4 antagonism, or utilizing deuterated vitamin A to slow dimerization; experimental approaches also include direct lysosomal clearance of existing deposits.